Referencias►
1.
Ross SA, Ziska DS, Zhoa K, et al. Variance of common flavonoids by brand of grapefruit juice.
Fitoterapia. 2000;71:154 - 161.
2.
Godeberge P. Daflon 500 mg in the treatment of hemorrhoidal disease: a demonstrated efficacy in comparison with placebo.
Angiology. 1994;45:574 - 578.
3.
Cospite M. Double-blind, placebo-controlled evaluation of clinical activity and safety of Daflon 500 mg in the treatment of acute hemorrhoids.
Angiology. 1994;45:566 - 573.
4.
Thanapongsathorn W, Vajrabukka T. Clinical trial of oral diosmin (Daflon) in the treatment of hemorrhoids.
Dis Colon Rectum. 1992;35:1085 - 1088.
5.
Misra MC, Parshad R. Randomized clinical trial of micronized flavonoids in the early control of bleeding from acute internal haemorrhoids.
Br J Surg. 2000;87:868 - 872.
6.
Ho YH, Tan M, Seow-Choen F. Micronized purified flavonidic fraction compared favorably with rubber band ligation and fiber alone in the management of bleeding hemorrhoids: randomized controlled trial.
Dis Colon Rectum. 2000;43:66 - 69.
7.
Tsouderos Y. Venous tone: are the phlebotonic properties predictive of a therapeutic benefit? A comprehensive view of our experience with Daflon 500 mg.
Z Kardiol. 1991;80(suppl 7):95 - 101.
8.
Ihme N, Kiesewetter H, Jung F, et al. Leg oedema protection from a buckwheat herb tea in patients with chronic venous insufficiency: a single-centre, randomised, double-blind, placebo-controlled clinical trial.
Eur J Clin Pharmacol. 1996;50:443 - 447.
9.
Guilhou JJ, Dereure O, Marzin L, et al. Efficacy of Daflon 500 mg in venous leg ulcer healing: a double-blind, randomized, controlled versus placebo trial in 107 patients.
Angiology. 1997;48:77 - 85.
10.
Guilhou JJ, Fevrier F, Debure C, et al. Benefit of a 2-month treatment with a micronized, purified flavonoidic fraction on venous ulcer healing. A randomized, double-blind, controlled versus placebo trial.
Int J Microcirc Clin Exp. 1997;17(Suppl 1):21 - 26.
11.
Guilhou JJ, Dereure O, Marzin L, et al. Efficacy of Daflon 500 mg in venous leg ulcer healing: a double-blind, randomized, controlled versus placebo trial in 107 patients.
Angiology. 1997;48:77 - 85.
12.
Guilhou JJ, Fevrier F, Debure C, et al. Benefit of a 2-month treatment with a micronized, purified flavonoidic fraction on venous ulcer healing. A randomized, double-blind, controlled versus placebo trial.
Int J Microcirc Clin Exp. 1997;17(Suppl 1):21 - 26.
13.
Galley P, Thiollet M. A double-blind, placebo-controlled trial of a new veno-active flavonoid fraction (S 5682) in the treatment of symptomatic capillary fragility.
Int Angiol. 1993;12:69 - 72.
14.
Pecking AP, Fevrier B, Wargon C, et al. Efficacy of Daflon 500 mg in the treatment of lymphedema (secondary to conventional therapy of breast cancer).
Angiology. 1997;48:93 - 98.
15.
Lee SH, Park YB, Bae KH, et al. Cholesterol-lowering activity of naringenin via inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase and acyl coenzyme A: cholesterol acyltransferase in rats.
Ann Nutr Metab. 1999;43:173 - 180.
16.
Shin YW, Bok SH, Jeong TS, et al. Hypocholesterolemic effect of naringin associated with hepatic cholesterol regulating enzyme changes in rats.
Int J Vitam Nutr Res. 1999;69:341 - 347.
17.
Emim JA, Oliveira AB, Lapa AJ. Pharmacological evaluation of the anti-inflammatory activity of a citrus bioflavonoid, hesperidin, and the isoflavonoids, duartin and claussequinone, in rats and mice.
J Pharm Pharmacol. 1994;46:118 - 122.
18.
Manuel y Keenoy B, Vertommen J, De Leeuw I. The effect of flavonoid treatment on the glycation and antioxidant status in Type 1 diabetic patients.
Diabetes Nutr Metab. 1999;12:256 - 263.
19.
Middleton E Jr, Drzewiecki G, Tatum J. The effects of citrus flavonoids on human basophil and neutrophil function.
Planta Med. 1987;53:325 - 328.
20.
So FV, Guthrie N, Chambers AF, et al. Inhibition of human breast cancer cell proliferation and delay of mammary tumorigenesis by flavonoids and citrus juices.
Nutr Cancer. 1996;26:167 - 181.
21.
Godeberge P. Daflon 500 mg in the treatment of hemorrhoidal disease: a demonstrated efficacy in comparison with placebo.
Angiology. 1994;45:574 - 578.
22.
Cospite M. Double-blind, placebo-controlled evaluation of clinical activity and safety of Daflon 500 mg in the treatment of acute hemorrhoids.
Angiology. 1994;45:566 - 573.
23.
Misra MC, Parshad R. Randomized clinical trial of micronized flavonoids in the early control of bleeding from acute internal haemorrhoids.
Br J Surg. 2000;87:868 - 872.
24.
Ho YH, Tan M, Seow-Choen F. Micronized purified flavonidic fraction compared favorably with rubber band ligation and fiber alone in the management of bleeding hemorrhoids: randomized controlled trial.
Dis Colon Rectum. 2000;43:66 - 69.
25.
Thanapongsathorn W, Vajrabukka T. Clinical trial of oral diosmin (Daflon) in the treatment of hemorrhoids.
Dis Colon Rectum. 1992;35:1085 - 1088.
26.
Guilhou JJ, Dereure O, Marzin L, et al. Efficacy of Daflon 500 mg in venous leg ulcer healing: a double-blind, randomized, controlled versus placebo trial in 107 patients.
Angiology. 1997;48:77 - 85.
27.
Ihme N, Kiesewetter H, Jung F, et al. Leg oedema protection from a buckwheat herb tea in patients with chronic venous insufficiency: a single-centre, randomised, double-blind, placebo-controlled clinical trial.
Eur J Clin Pharmacol. 1996;50:443 - 447.
28.
Galley P, Thiollet M. A double-blind, placebo-controlled trial of a new veno-active flavonoid fraction (S 5682) in the treatment of symptomatic capillary fragility.
Int Angiol. 1993;12:69 - 72.
29.
Miller MJ. Injuries to athletes. Evaluation of ascorbic acid and water soluble citrus bioflavonoids in the prophylaxis of injuries in athletes.
Med Times. 1960;88:313 - 316.
30.
Meyer OC. Safety and security of Daflon 500 mg in venous insufficiency and in hemorrhoidal disease.
Angiology. 1994;45:579 - 584.
31.
Buckshee K, Takkar D, Aggarwal N. Micronized flavonoid therapy in internal hemorrhoids of pregnancy.
Int J Gynaecol Obstet. 1997;57:145 - 151.
32.
Bracke ME, Depypere HT, Boterberg T, et al. Influence of tangeretin on tamoxifen's therapeutic benefit in mammary cancer.
J Natl Cancer Inst. 1999;91:354 - 359.
33.
Strick R, Strissel PL, Borgers S, et al. Dietary bioflavonoids induce cleavage in the MLL gene and may contribute to infant leukemia.
Proc Natl Acad Sci. 2000;97:4790 - 4795.
34.
Laurent R, Gilly R, Frileux C. Clinical evaluation of a venotropic drug in man. Example of Daflon 500 mg.
Int Angiol.
1988;7:39-43.
35.
Danielsson G, Jungbeck C, Peterson K, et al. A randomised controlled trial of micronised purified flavonoid fraction vs placebo in patients with chronic venous disease.
Eur J Vasc Endovasc Surg.
2002;23:73 - 76.
36.
Manthey JA, Grohmann K, Guthrie N. Biological properties of citrus flavonoids pertaining to cancer and inflammation.
Curr Med Chem. 2001;8:135 - 153.
37.
Cluzan RV, Alliot F, Ghabboun S, et al. Treatment of secondary lymphedema of the upper limb with CYCLO 3 FORT.
Lymphology. 1996;29:29 - 35.
